ASH 2021
Fred Hutchinson Cancer Research Center’s latest findings on transplantation, cell therapies, precision medicine and more will be featured at the 63nd Annual Meeting and Exposition of the American Society of Hematology (ASH).
This year's annual meeting will be held both in-person at the Georgia World Congress Center in Atlanta, and as a virtual event .
The ASH meeting provides an invaluable educational experience and the latest on the hottest topics in hematology. Attendees include top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.
The meeting features the annual E. Donnall Thomas Lecture, named for the Fred Hutch physician-scientist who was awarded the Nobel Prize in physiology or medicine for his development of bone marrow transplantation.
Visit the Fred Hutch/Seattle Cancer Care Alliance booth in the Virtual Exhibit Hall.
Highlights of Fred Hutch Presentations at ASH
Preclinical Therapeutics Development | Clinical Trials | Biomarkers, Diagnostics, Prognostics | Transplantation Biology | COVID-19
Oral Presentation: The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT
Abstract No. 328
Presenter: Simone Minnie, Ph.D.
Saturday, Dec. 11, 4 p.m.
Oral Presentation: Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL
Abstract No. 509
Presenter: Quy Le, Ph.D.
Sunday, Dec. 12, 4:30 P.M.
Poster Presentation: Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML
Abstract No. 2788
Presenter: Quy Le, Ph.D.
Sunday, Dec. 12, 6 p.m.
Poster Presentation: Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy
Abstract No. 2776
Presenter: Salvatore Fiorenza, Ph.D.
Sunday, Dec. 12, 6 p.m.
Poster Presentation: Efficient Nanoparticle-Mediated Delivery of Gene Editing Reagents into Human Hematopoietic Stem and Progenitor Cells
Abstract No. 2933
Presenter: Stefan Radtke, Ph.D.
Sunday, Dec. 12, 6 p.m.
Featured in the ASH Poster Walk on Emerging Research in Immunotherapies, Dec. 16, 5-6 p.m.
Poster Presentation: Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL
Abstract No. 3872
Presenter: Mazyar Shadman, M.D.
Monday, Dec. 13, 6 p.m.
Oral Presentation: Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
Abstract No. 551
Presenter: Andrew Cohen, M.D.
Sunday, Dec. 12, 4:30 p.m.
Poster Presentation: Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
Abstract No. 2816
Presenter: Nicolas Gazeau, Ph.D.
Sunday, Dec. 12, 6 p.m.
Oral Presentation: Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions
Abstract No. 802
Presenter Rhonda E. Ries, M.A.
Monday, Dec. 13, 4:30 p.m.
Oral Presentation: Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children’s Oncology Group
Abstract No. 519
Presenter: Katherine Tarlock, M.D.
Sunday, Dec. 12, 4:30 p.m.
Poster Presentation: Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG
Abstract No. 799
Presenter: Derek Stirewalt, M.D.
Monday, Dec. 13, 4:30 p.m.
Oral Presentation: Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report
Abstract No. 522
Presenter: Jasmine Naru
Sunday, Dec. 12, 4:30 p.m.
Oral Presentation: Single-Cell Transcriptomics for Residual Disease Detection in Acute Myelogenous Leukemia Post Allogeneic Hematopoietic Cell Transplantation
Abstract No. 518
Presenter: Scott Furlan, M.D.
Sunday, Dec. 12, 4:30 p.m.
Oral Presentation: Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients
Abstract No. 645
Presenter: Keith Loeb, M.D., Ph.D.
Monday, Dec. 13, 10:30 a.m.
Oral Presentation: Non-Genetic Determinants of Clonotypic T Cell Expansion Following Allogeneic Stem Cell Transplant
Abstract No. 646
Presenter: Albert Yeh, M.D.
Monday, Dec. 13, 10:30 a.m.
Oral Presentation: Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition
Abstract No. 648
Presenter: Ping Zhang, M.D.
Monday, Dec. 13, 10:30 a.m.
Poster Presentation: High-Density Clonal Analysis Reveals Highly Active Contribution of Multipotent Hematopoietic Stem Cells during Early Phases of Hematopoietic Recovery after Transplantation
Abstract No. 3258
Presenter: Stefan Radtke, Ph.D.
Monday, Dec. 13, 6 p.m.
Poster Presentation: COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
Abstract No. 2868
Presenter: Neel Bhatt, M.B.B.S., M.P.H.
Saturday, Dec. 12, 6 p.m.
Other Fred Hutch Experts with Research at ASH
ASH Conference Media Coverage
Younger Hispanic/Latinx patients face access barriers to CAR-T clinical trials
Helio.com | January 6, 2022
J&J's new CAR-T therapy shows long-term success, data show
STAT | By Angus Chen | December, 12, 2021
Dr. Shadman on the safety profile of a CD20-directed CAR T-Cell therapy in B-NHL and CLL
OncLive | December 22, 2021
ASH Highlights: Hematopoietic Stem Cell Transplantation
Oncology Tube | March 2, 2022
Contact Our Media Relations Team
For more information or to arrange an interview, please email or call our media relations team.